Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Mushroom coffee: Worth a taste
Recent research suggests semaglutide drugs may be linked to serious eye conditions, including non-arteritic anterior ischemic optic neuropathy (NAION)
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
Border town pharmacies in cities like Tijuana, Nogales, and Ciudad Juarez also stock Mounjaro, catering specifically to the growing medical tourism market
The Precision Peptide Genetic Test ($298) maps your GLP-1 receptor and appetite-control pathways, helping PlexusDx clinicians personalize your dose to produce strong appetite suppression that naturally reinforces consistent injection behavior
